You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Article metrics

Article menu

Download PDFPDF

E-Poster viewings
Trials in Progress
IGCS19-0383
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Free

 

Online download statistics by month:

Online download statistics by month: September 2019 to September 2024

AbstractFullPdf
Sep 201928012
Oct 201966013
Nov 20196807
Dec 201954011
Jan 20209207
Feb 202062011
Mar 202034010
Apr 20205007
May 20204604
Jun 20204809
Jul 202066010
Aug 202074012
Sep 20206807
Oct 202070012
Nov 202064012
Dec 20203803
Jan 20215109
Feb 20212604
Mar 20215607
Apr 20216409
May 202161011
Jun 20210021
Jul 20212016
Aug 2021008
Sep 20210028
Oct 2021108039
Nov 202166022
Dec 2021116011
Jan 20227809
Feb 202262010
Mar 20226606
Apr 20224808
May 20228006
Jun 202224010
Jul 20223903
Aug 20225009
Sep 20222802
Oct 20225506
Nov 20224006
Dec 20224804
Jan 20233402
Feb 20234201
Mar 20235207
Apr 20232607
May 20235707
Jun 20233800
Jul 20233604
Aug 20235502
Sep 20232605
Oct 20235204
Nov 20233204
Dec 202310101
Jan 20241803
Feb 20241803
Mar 202431030
Apr 20242005
May 20244003
Jun 20242002
Jul 20242204
Aug 20242409
Sep 2024802
Total28480516